CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 410 enrolled
Drug / intervention
Brenetafusp +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04262466
NCT04262466Phase 2Active
CompareCT.gov

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

Immunocore Ltd·interventional·Posted Feb 10, 2020·Updated Mar 6, 2026

In Brief

A Phase 2 clinical trial evaluating Brenetafusp, Brenetafusp and pembrolizumab, and 5 other interventions for Select Advanced Solid Tumors. Active but no longer recruiting, targeting 410 participants across 76 sites in 17 countries.

Detailed Summary

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSelect Advanced Solid Tumors
CountriesAustralia, Austria, Belgium, Brazil, Canada, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, South Korea, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2Active
202020212022202320242025202620272028
First PostedFeb 10, 2020
Enrollment StartFeb 25, 2020
Primary CompletionOct 1, 2026
Study CompletionDec 1, 2027
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 6.4 years agoPrimary completion in 3 months

Interventions

Brenetafuspdrug

Brenetafusp IV infusions

Brenetafusp and pembrolizumabdrug

Brenetafusp and pembrolizumab IV infusions

Brenetafusp and chemotherapydrug

Brenetafusp and chemotherapy IV infusions

Brenetafusp and monoclonal antibodies and chemotherapydrug

Brenetafusp and a monoclonal antibody therapy and chemotherapy

Brenetafusp and tebentafuspdrug

Brenetafusp and tebentafusp IV infusions

Brenetafusp and bevacizumabdrug

Brenetafusp and bevacizumab IV infusions

Brenetafusp and kinase inhibitorsdrug

Brenetafusp and oral kinase inhibitors